Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Bastiaan M PrivéMarcel J R JanssenInge M van OortConstantijn H J MuselaersMarianne A JonkerMichel de GrootNiven MehraJ Fred VerzijlbergenTom W J ScheenenPatrik ZámecnikJelle O BarentszMartin GotthardtWalter NoordzijWouter V VogelAndries M BergmanHenk G van der PoelAndré N VisDaniela E Oprea-LagerWinald R GerritsenJ Alfred WitjesJames NagarajahPublished in: BMC cancer (2020)
Clinicaltrials.gov identifier: NCT04443062 .